Monitoring the safety of medicines throughout their life cycle (pharmacovigilance) is the responsibility of the European Medicines Agency (EMA) on behalf of Member States. The European Commission has published a report, accompanied by a detailed Staff Working document, describing the activities of the collaborative EU system for monitoring and controlling the safety of human medicines. […]
Monitoring medicine safety in the EU Read More »
Delivering on its Strategy to create a Digital Single Market, the European Commission has developed plans to help European industry, SMEs, researchers and public authorities make the most of new technologies. It has created a set of measures to support and link up national initiatives for the digitisation of industry and related services across all
Digitising European public services Read More »
Fifty-nine UK-based researchers are to receive up to €1.5 million (£1.3m) each to set up their own research teams and pursue ground-breaking ideas under the EU’s European Research Council (ERC) latest round of starting grants. These grants come from the ‘excellent science’ pillar of Horizon 2020, the EU’s research and innovation programme. The UK is
UK-based researchers benefit from latest EU funding Read More »
Antimicrobial resistance is a global crisis that threatens public health and modern medicine. The discovery and development of novel antibiotic products are critical components in combating it. Many international, EU and national initiatives address the scientific, regulatory and economic barriers to antibiotic innovation. This study identifies, reviews and critically assesses these initiatives, and provides policy recommendations
Antibiotic drug discovery Read More »
The European Commission has published a report on activities by Member States and the European Medicines Agency (EMA), to monitor the safety of medicines throughout their life cycle (a process called ‘pharmacovigilance’). The aim of EU rules on pharmacovigilance is to monitor the safety of medicines so that regulators can take action to reduce the
The EU pharmacovigilance system Read More »
Breast cancer is the most common cancer in Europe. It is the most deadly cancer in women: one out of every six women with cancer will die from breast cancer. In addition, incidence and mortality rates for breast cancer vary widely between countries: although a higher mortality rate in some countries may be due to
Breast cancer care Read More »
The European Commission’s 3-year initiative ‘Ex-smokers are unstoppable’ has now finished but it proved enormously successful with one in three of the 480,000 registered users stopping smoking after three months. The centre-piece of the programme was the iCoach, a digital health coach which was free and available both online and as a mobile app for
Ex smokers are unstoppable Read More »
The health sector represents 10{ddf8d179d1bf712bb2a88ff2ad95ebdf63eaa5463c845d2f093b25848387ba96} of the EU’s GDP and accounts for 8{ddf8d179d1bf712bb2a88ff2ad95ebdf63eaa5463c845d2f093b25848387ba96} of the total European workforce. It is a vital economic sector strongly driven by innovation and is a growth-friendly area for investment. The European Fund for Strategic Investments (EFSI) can support investment in innovative health solutions, new effective medicines and social infrastructures.
Investing in innovative health solutions Read More »
Global consumption of antibiotics in human medicine rose by nearly 40{ddf8d179d1bf712bb2a88ff2ad95ebdf63eaa5463c845d2f093b25848387ba96} in the decade from 2000 and in 2007 25,000 people a year in the EU were dying from an infection due to antibiotic-resistant bacteria. Infections due to these multi-drug resistant bacteria are estimated to cost the EU at least €1.5 billion a year in
Need for greater EU action on antimicrobial resistance Read More »
Endocrine disruptors are chemicals which impact on the hormone system of animals and humans. They have three cumulative characteristics: a hormonal function, an adverse effect, and a causality between the two. There has been increasing interest in endocrine disruptors and the European Commission has produced a factsheet that answers some of the most common questions
Endocrine disruptors Read More »
